SCHEMBL1797816

SCHEMBL1797816

CCOc1nc(-c2c[nH]c3ncc(C4CCCCC4)cc23)cs1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MAPK9 P45984 3/20 0.37
▸ MAPK8 P45983 2/20 0.37
▸ MAPK10 P53779 2/20 0.37
▸ PDPK1 O15530 7/20 0.36
▸ PIK3CA P42336 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ ROCK1 Q13464 3/20 0.34
▸ IL2 P60568 2/20 0.34
▸ MAP4K1 Q92918 2/20 0.34
▸ CDC7 O00311 2/20 0.34
▸ ROCK2 O75116 2/20 0.34
▸ MAP4K4 O95819 2/20 0.34
▸ CDK1 P06493 2/20 0.34
▸ PRKACA P17612 2/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ HIPK2 Q9H2X6 2/20 0.34
▸ MKNK2 Q9HBH9 2/20 0.34
▸ SGK2 Q9HBY8 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1801749 0.90 IL2 (0.39) MAPK9MAPK8MAPK10PIK3CAROCK1
SCHEMBL1799003 0.84 MAPK9 (0.40) MEN1KMT2AMAPK9MAPK8MAPK10
SCHEMBL1800744 0.84 MAPK8 (0.59) MAPK9MAPK8MAPK10PIK3CGIL2
SCHEMBL1800743 0.84 MAPK8 (0.59) MAPK9MAPK8MAPK10PIK3CGIL2
SCHEMBL1798817 0.83 MAPK8 (0.62) MAPK9MAPK8MAPK10PIK3CGIL2
SCHEMBL1798815 0.83 MAPK8 (0.62) MAPK9MAPK8MAPK10PIK3CGIL2
SCHEMBL8167221 0.78 MAPK9 (0.39) MEN1KMT2AMAPK9MAPK8MAPK10
SCHEMBL1796713 0.78 CAMKK2 (0.43) KMT2AMAPK9MAPK8MAPK10ROCK1
SCHEMBL1796697 0.78 IL2 (0.44) MAPK9MAPK8MAPK10ROCK1IL2
SCHEMBL1796868 0.77 CAMKK2 (0.39) MAPK9MAPK8MAPK10ROCK1MAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed
EP-2125801-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE Eisai R&D Management Co., Ltd. (JP) 2009-12-02 — — EP disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed
WO-2008095943-A1 THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO. LTD. (JP) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPKAPK5, MAPK13 MEN1 2805/4885KMT2A 799/4885MAPK9 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback